After the 2026 FDA decision, people with early Alzheimer's can start Leqembi at home with a weekly injection instead of traveling for IV infusions. That change reopens follow-up decisions about starting route, switching routes, and safety monitoring. Leqembi (lecanemab-irmb) is a treatment that targets amyloid-beta plaques in the brain. It is for adults with mild cognitive impairment or mild dementia due to early Alzheimer's.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official guidance from Prnewswire — Use this primary source to verify the official guidance.
- Apply through Cision’s official page — Use this page to review requirements and apply directly.
Table of Contents
- Who can consider the at-home start
- What is different about injections versus infusions
- Can you start one way and switch later
- What safety follow-up still needs a clinic
- Frequently Asked Questions
Who can consider the at-home start
Treatment requires confirmed amyloid-beta pathology before the first dose. It is for adults with mild cognitive impairment or mild dementia due to early Alzheimer's.
A diagnosis of memory symptoms alone is not enough. A clinician must confirm amyloid with an appropriate test and confirm the stage fits early disease.
What is different about injections versus infusions
The starting injection regimen is 500 mg weekly, given as two 250-mg injections of about 15 seconds each, according to the BioArctic and Eisai announcement FDA approval notice. Maintenance is 360 mg weekly after 18 months of treatment.
The injections use an autoinjector and allow at-home initiation. IV lecanemab used 10 mg/kg every two weeks and took about an hour per infusion, according to Medscape reporting Medscape report. An earlier subcutaneous option covered only maintenance after 18 months of IV therapy.
- IV start: clinic visits every two weeks, longer appointment, infusion staff present
- Injection start: weekly doses at home, two short injections, less travel time
- Both routes: same eligibility testing, prescription, and safety monitoring
Can you start one way and switch later
Patients may now start with either IV infusion or subcutaneous injection. They may also switch between routes without restarting therapy. That continuity matters for practical disruptions.
A move, caregiver change, infusion-center delay, or injection difficulty does not mean starting over. Talk with the prescribing team before switching. Dose, timing, records, and follow-up scans must transfer cleanly between settings.
What safety follow-up still needs a clinic
Lecanemab carries a risk of ARIA, meaning brain swelling or bleeding. Risk is highest in people with two copies of ApoE ε4, according to a Denkstrom summary of FDA prescribing information prescribing-information summary.
At-home dosing does not remove hospital-based checks. Patients still need baseline and follow-up MRIs, a discussion about ApoE testing, and clinician-supervised first doses.
- Ask when baseline MRI, ApoE discussion, and first supervised doses occur
- Ask how many follow-up MRIs are scheduled and where they occur
- Ask whom to call promptly for headache, confusion, dizziness, vision change, or unusual bleeding
Frequently Asked Questions
Does the injection work the same as the infusion?
Approval relied on comparable drug exposure and amyloid clearance, with open-label data showing greater early plaque clearance for the injection route.
Do home injections end MRI visits?
No. Baseline and follow-up MRIs remain required because of ARIA risk, with closer attention for ApoE ε4 homozygotes.
